Coronavirus Vaccine Latest Update: Oxford Vaccine Found “SAFE” In Early Trials; Triggers Immune System Response

8Lancet Journal has publised Oxford vaccine's early trial data

Oxford vaccine found “SAFE” in early trials, result published in The Lancet Journal

The highly infectious novel coronavirus is spreading at a record rate globally as the number of positive coronavirus infections is inching closer to the 15 million mark. The world has put a determined front to contain the spread of the contagion which has caused more the 6 lakh fatalities worldwide. The good news amidst all the chaos is that out of the 155+ vaccine candidates in various stages of trials, 


The much-awaited result of Phase I/II trials of the Oxford University’s vaccine candidate ‘AZD1222’ has just been released and it just might be the first piece of good news in 2020. The results which have been published in the medical journal The Lancet reinstate the earlier media reports which cited that Oxford’s vaccine candidate is fit for human use and develops protective immunity in the body of the volunteers. As per the latest update, Richard Horton, the editor of the UK-based science journal ‘The Lancet’ noted that “the vaccine is safe, well-tolerated, and immunogenic.” He also underlined that the results were “extremely encouraging.”



For the unversed, stage III of clinical trials (or human trials) is where medical experts and scientists dose thousands of volunteers with the vaccine candidate to understand if the vaccination provides active protection against the coronavirus. This is the final stage trial done just before getting approval from the regulatory authorities to launch the vaccine for mass-usage. As of now, vaccine candidates developed by the  oxford uni..
Chinese company Sinopharm and Chinese pharmaceutical giant Sinovac have reached the Phase III of human trials.